A Phase 4 interventional study of ruxolitinib cream in Atopic Dermatitis, sponsored by Incyte Corporation. Terminated at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Incyte Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 12th largest by enrollment, is the only one that started in 2023, is one of 3 in phase 4, and was the 11th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 2+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 77 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 3 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
17 studies in Dermatitis, Atopic by Incyte Corporation: 2 open now, 3 under way, 1 of them phase 3. Of 14 finished, 10 (71%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2023, is the only one in phase 4, and was the 11th registered.
Incyte Corporation’s Dermatitis, Atopic studies by the year they started, since 2017.
1 of the studies testing ruxolitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661979Wake Forest University Health SciencesOpzelura Experience Study | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Incyte Corporation’s 17 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ruxolitinib cream 1.5% will be applied twice daily (BID) as a thin film.
Drug: ruxolitinib cream
ruxolitinib cream 1.5% will be applied twice daily as a thin film
Also known as: INCB018424
Change From Baseline in Total Sleep Time (TST) as Measured by Ōura Ring Wearable Device at Week 8
TST is the total amount of time spent during a planned sleep episode. Decreased TST is indicative of increased sleep disturbance. Baseline TST was the average hours of sleep within the last 7 nights prior to Visit 1. The Week 8 TST was the average hours of sleep within the last 7 nights prior to Visit 3/Week 8. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Week 8
Change From Baseline in PROMIS Sleep Disturbance - Short Form 8b Score (24-hour Recall) at Week 8
The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form 8b is a validated instrument used to measure the severity of sleep disturbance. The PROMIS score includes 8 items, each of which asks the participant to rate the severity of their sleep disturbance on a daily basis on a severity scale of 1 to 5. The PROMIS total score is calculated as the sum of the 8 items and ranges from 8 to 40. A higher PROMIS score indicates more severe sleep disturbance. The baseline score was the 7-day average of nonmissing scores for the 6 days preceding a participant's Visit 1 and their response at Visit 1. Week 8 scores comprised the 7-day average of nonmissing scores for the 6 days preceding a participant's Visit 3 and their response at Visit 3. The average was not valid and was set to missing if scores were missing on 4 or more days. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Week 8
| Milestone | Ruxolitinib 1.5% Cream BID |
|---|---|
| Started | 47 |
| Completed | 42 |
| Not completed | 5 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 1 |
TST is the total amount of time spent during a planned sleep episode. Decreased TST is indicative of increased sleep disturbance. Baseline TST was the average hours of sleep within the last 7 nights prior to Visit 1. The Week 8 TST was the average hours of sleep within the last 7 nights prior to Visit 3/Week 8. Change from baseline was calculated as the post-baseline value minus the baseline value.
| hours | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 5.69 ± 0.956 |
| Change from baseline at Week 8 | 0.09 ± 1.145 |
The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form 8b is a validated instrument used to measure the severity of sleep disturbance. The PROMIS score includes 8 items, each of which asks the participant to rate the severity of their sleep disturbance on a daily basis on a severity scale of 1 to 5. The PROMIS total score is calculated as the sum of the 8 items and ranges from 8 to 40. A higher PROMIS score indicates more severe sleep disturbance. The baseline score was the 7-day average of nonmissing scores for the 6 days preceding a participant's Visit 1 and their response at Visit 1. Week 8 scores comprised the 7-day average of nonmissing scores for the 6 days preceding a participant's Visit 3 and their response at Visit 3. The average was not valid and was set to missing if scores were missing on 4 or more days. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 27.58 ± 4.955 |
| Change from baseline at Week 8 | -7.47 ± 7.802 |
Collected over up to 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib 1.5% Cream BID | 0/47 (0%) | 0/47 (0%) | 7/47 (14.9%) |
| Event | Ruxolitinib 1.5% Cream BID |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/47 |
| Application site painGeneral disorders | 1/47 |
| NasopharyngitisInfections and infestations | 1/47 |
| FallInjury, poisoning and procedural complications | 1/47 |
| Muscle strainInjury, poisoning and procedural complications | 1/47 |
| Blood creatine phosphokinase increasedInvestigations | 1/47 |
| Joint swellingMusculoskeletal and connective tissue disorders | 1/47 |
| Age, Continuous(years) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Mean | 40.9 ± 16.43 |
| Sex: Female, Male(Participants) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Female | 27 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 39 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Asian | 8 |
| Black or African American | 16 |
| Not Reported | 1 |
| Captured as "Other" in Database | 1 |
| White | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Mar 2023 to primary completion in Jan 2025, 22 months.
Results were first posted in Dec 2025, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib